BUSINESS
Stemirac’s 44 Million Yen Sales Within Expectations, Says Nipro President
Nipro’s Stemirac, the first stem cell therapy for spinal cord injury conditionally approved in Japan late last year, generated sales of 44 million yen between its launch in May and the end of September, and President Yoshihiko Sano says the…
To read the full story
Related Article
- Stemirac Posts 130 Million Yen Sales in May-December: Nipro
February 10, 2020
- Reducing Production Cost of Stemirac Is Key Issue: Nipro Pres.
May 20, 2019
BUSINESS
- Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
May 1, 2026
- Rohto Files CMV Corneal Endotheliitis Drug in Japan
May 1, 2026
- Mochida Files in Japan for PAH Drug Tyvaso DPI
May 1, 2026
- Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
May 1, 2026
- 3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
May 1, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





